Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed Mu opioid receptors
- PMID: 18319252
- DOI: 10.1074/jbc.M710300200
Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed Mu opioid receptors
Abstract
The human mu opioid receptor was expressed stably in Flp-In T-REx HEK293 cells. Occupancy by the agonist DAMGO (Tyr-d-Ala-Gly-N-methyl-Phe-Gly-ol) resulted in phosphorylation of the ERK1/2 MAP kinases, which was blocked by the opioid antagonist naloxone but not the cannabinoid CB1 receptor inverse agonist SR141716A. Expression of the human cannabinoid CB1 receptor in these cells from the inducible Flp-In T-REx locus did not alter expression levels of the mu opioid receptor. This allowed the cannabinoid CB1 agonist WIN55212-2 to stimulate ERK1/2 phosphorylation but resulted in a large reduction in the capacity of DAMGO to activate these kinases. Although lacking affinity for the mu opioid receptor, co-addition of SR141716A caused recovery of the effectiveness of DAMGO. In contrast co-addition of the CB1 receptor neutral antagonist O-2050 did not. Induction of the CB1 receptor also resulted in an increase of basal [(35)S]guanosine 5'-3-O-(thio)triphosphate (GTPgammaS) binding and thereby a greatly reduced capacity of DAMGO to further stimulate [(35)S]GTPgammaS binding. CB1 inverse agonists attenuated basal [(35)S]GTPgammaS binding and restored the capacity of DAMGO to stimulate. Flp-In T-REx HEK293 cells were generated, which express the human mu opioid receptor constitutively and harbor a modified D163N cannabinoid CB1 receptor that lacks constitutive activity. Induction of expression of the modified cannabinoid CB1 receptor did not limit DAMGO-mediated ERK1/2 MAP kinase phosphorylation and did not allow SR141716A to enhance the function of DAMGO. These data indicate that it is the constitutive activity inherent in the cannabinoid CB1 receptor that reduces the capacity of co-expressed mu opioid receptor to function.
Similar articles
-
CB1 receptor-independent actions of SR141716 on G-protein signaling: coapplication with the mu-opioid agonist Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol unmasks novel, pertussis toxin-insensitive opioid signaling in mu-opioid receptor-Chinese hamster ovary cells.J Pharmacol Exp Ther. 2009 Aug;330(2):567-74. doi: 10.1124/jpet.109.152710. Epub 2009 May 15. J Pharmacol Exp Ther. 2009. PMID: 19448142
-
Inhibition of forebrain μ-opioid receptor signaling by low concentrations of rimonabant does not require cannabinoid receptors and directly involves μ-opioid receptors.Neurochem Int. 2012 Aug;61(3):378-88. doi: 10.1016/j.neuint.2012.05.015. Epub 2012 May 18. Neurochem Int. 2012. PMID: 22613132
-
Central effects of the cannabinoid receptor agonist WIN55212-2 on respiratory and cardiovascular regulation in anaesthetised rats.Br J Pharmacol. 2004 Jul;142(6):943-52. doi: 10.1038/sj.bjp.0705874. Epub 2004 Jun 28. Br J Pharmacol. 2004. PMID: 15226190 Free PMC article.
-
Role of phospholipase D2 in the agonist-induced and constitutive endocytosis of G-protein coupled receptors.J Neurochem. 2006 Apr;97(2):365-72. doi: 10.1111/j.1471-4159.2006.03736.x. Epub 2006 Mar 15. J Neurochem. 2006. PMID: 16539674
-
The cannabinoid receptor agonists, anandamide and WIN 55,212-2, do not directly affect mu opioid receptors expressed in Xenopus oocytes.Naunyn Schmiedebergs Arch Pharmacol. 2007 Dec;376(4):285-93. doi: 10.1007/s00210-007-0201-7. Epub 2007 Oct 25. Naunyn Schmiedebergs Arch Pharmacol. 2007. PMID: 17960365
Cited by
-
Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats.Pharmacol Biochem Behav. 2008 Nov;91(1):84-90. doi: 10.1016/j.pbb.2008.06.014. Epub 2008 Jun 29. Pharmacol Biochem Behav. 2008. PMID: 18640150 Free PMC article.
-
Marijuana-based drugs: innovative therapeutics or designer drugs of abuse?Mol Interv. 2011 Feb;11(1):36-51. doi: 10.1124/mi.11.1.6. Mol Interv. 2011. PMID: 21441120 Free PMC article. Review.
-
Sulfation of the FLAG epitope is affected by co-expression of G protein-coupled receptors in a mammalian cell model.Sci Rep. 2016 Jun 7;6:27316. doi: 10.1038/srep27316. Sci Rep. 2016. PMID: 27273047 Free PMC article.
-
Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes.Pharmacol Rev. 2010 Dec;62(4):701-25. doi: 10.1124/pr.110.002667. Pharmacol Rev. 2010. PMID: 21079041 Free PMC article. Review.
-
Agonist activation of the G protein-coupled receptor GPR35 involves transmembrane domain III and is transduced via Gα₁₃ and β-arrestin-2.Br J Pharmacol. 2011 Feb;162(3):733-48. doi: 10.1111/j.1476-5381.2010.01082.x. Br J Pharmacol. 2011. PMID: 20958291 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous